Last reviewed · How we verify
Midazolam and Qualaquin at steady state — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Midazolam and Qualaquin at steady state (Midazolam and Qualaquin at steady state) — Mutual Pharmaceutical Company, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Midazolam and Qualaquin at steady state TARGET | Midazolam and Qualaquin at steady state | Mutual Pharmaceutical Company, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Midazolam and Qualaquin at steady state CI watch — RSS
- Midazolam and Qualaquin at steady state CI watch — Atom
- Midazolam and Qualaquin at steady state CI watch — JSON
- Midazolam and Qualaquin at steady state alone — RSS
Cite this brief
Drug Landscape (2026). Midazolam and Qualaquin at steady state — Competitive Intelligence Brief. https://druglandscape.com/ci/midazolam-and-qualaquin-at-steady-state. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab